Cytochrome P450 enzyme mutants and uses thereof
By constructing and screening cytochrome P450 enzyme mutants, the problems of low efficiency and poor selectivity in steroid drug synthesis were solved, and the 6β hydroxylation of sterol compounds was achieved efficiently catalyzed, promoting the industrial production of steroid drugs.
Patent Information
- Application Number
- CN202411263442.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the chemical synthesis of steroid drugs has problems such as low synthesis efficiency, long time and large amount of organic reagents, and there is a lack of effective technical solutions for promoting the bioconversion of steroid compound intermediates such as bisal alcohols.
By constructing cytochrome P450 enzyme mutants, specifically including performing specific amino acid mutations on the amino acid sequence, such as Y256A, G87A, L82F, etc., a mutant library is formed, and mutants that catalyze the 6β hydroxylation reaction of sterol compounds are screened to generate 6β β -Hydroxylated sterol compounds.
It has achieved efficient catalysis of steroid drug intermediates, significantly improved catalytic activity and selectivity, and promoted the industrial production of steroid drugs.
Smart Images

Figure CN118773154B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biological enzyme technology, and in particular to a cytochrome P450 enzyme mutant and its use. Background Art
[0002] Steroid drugs are often used to prevent or treat obesity, diabetes, rheumatoid arthritis, asthma and other related diseases because of their pharmacological activities such as anti-inflammatory, anti-cancer, anti-allergic and contraceptive. At present, steroid drugs are mainly prepared by chemical or biocatalytic synthesis; among them, the traditional chemical synthesis route has problems such as low synthesis efficiency, long synthesis time and large amount of organic reagents used; in order to solve the problems existing in chemical synthesis, fermentation is used to degrade the side chain of plant sterols to obtain steroid compound intermediates, and then the steroid compound intermediates (such as dihydrocholine) are structurally modified by biocatalysis, which to a certain extent solves the problem in the field of pure chemical synthesis.
[0003] Cytochrome P450 (CYP) enzymes have a variety of biocatalytic activities such as hydroxylation, dealkylation, deamination, desulfurization, dehalogenation, sulfoxide oxidation, N-oxide reduction, epoxidation and demethylation. They can participate in many important reactions such as drug, steroid and carcinogen metabolism, and play an important role in the synthesis of steroid drugs and drug intermediates. However, there are few reports on the technical solutions for promoting the biotransformation of steroid intermediates such as bis-decanoyl alcohol (BA) using cytochrome P450 enzymes.
[0004] Therefore, discovering suitable P450 enzymes and modifying their structures are of great significance for achieving the efficient synthesis of steroid drugs and promoting the industrial production of steroid drugs. Summary of the invention
[0005] The purpose of the present application is to provide a cytochrome P450 enzyme mutant and its use.
[0006] To achieve the above objectives, the present application proposes the following technical solutions:
[0007] In a first aspect, the present invention provides a cytochrome P450 enzyme mutant, wherein the mutant has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2:
[0008] Y256A, Y256A+G87A, Y256A+G87A+L82W, Y256A+G87A+L82F, Y256A+G87A+L82 T, Y256A+G87A+T260S, Y256A+G87A+W330F, Y256A+G87A+W330T, Y256A+G87A +L82F+A74L、Y256A+G87A+L82F+A74M、Y256A+G87A+L82F+A74Q、Y256A+G87A+ L82F+T209V, Y256A+G87A+L82F+T209I, Y256A+G87A+L82F+T209F, Y256A+G87A +L82F+I263A, Y256A+G87A+L82F+A264G, Y256A+G87A+L82F+T209I+I81L, Y2 56A+G87A+L82F+T209I+I81T, Y256A+G87A+L82F+T209I+A184Q, Y256A+G87A+ L82F+ T209I+A184L, Y256A+G87A+L82F+T209I+A184F.
[0009] In a second aspect, an embodiment of the present application provides a DNA molecule comprising a nucleotide sequence encoding the cytochrome P450 enzyme mutant as described in the first aspect or its complementary sequence.
[0010] In a third aspect, an embodiment of the present application provides a recombinant plasmid, wherein the recombinant plasmid contains the DNA molecule as described in the second aspect.
[0011] In a fourth aspect, an embodiment of the present application provides a recombinant strain, wherein the recombinant strain contains the recombinant plasmid as described in the third aspect.
[0012] In a fifth aspect, the embodiments of the present application provide the use of the cytochrome P450 enzyme mutant described in the first aspect, the DNA molecule described in the second aspect, the recombinant plasmid described in the third aspect, or the recombinant strain described in the fourth aspect for catalyzing the 6β-hydroxylation reaction of a sterol compound to generate a 6β-hydroxylated sterol compound; wherein the sterol compound is selected from one of the following compounds:
[0013] .
[0014] As an embodiment, the preparation method of the 6β-hydroxylated sterol compound comprises:
[0015] preparing a recombinant plasmid containing a cytochrome P450 enzyme mutant;
[0016] Transforming the recombinant plasmid into a host cell to obtain a recombinant strain;
[0017] Using sterol compounds as substrates, in the presence of O2 and NADPH, the recombinant strain is used to catalyze the 6β-hydroxylation reaction of the sterol compounds to obtain 6β-hydroxylated sterol compounds.
[0018] The embodiments of the present application have at least the following beneficial effects:
[0019] The example of the present application uses the amino acid sequence shown in SEQ ID NO. 2 as a template (basis), performs mutation modification on the key active sites of the template (basis), constructs a mutant library, and screens to obtain a series of mutants with significantly improved catalytic activity and / or selectivity; the cytochrome P450 enzyme mutant provided in the example of the present application can selectively catalyze the 6β-hydroxylation reaction of sterol compounds to generate corresponding 6β-hydroxylated sterol compounds (steroid drugs), has excellent selectivity and / or high yield, indicating that the mutant has good application prospects in catalyzing steroid compounds to prepare 6β-hydroxysterol compounds.
[0020] Additional aspects and advantages of the present application will be partially given in the following description, which will become apparent from the following description, or will be understood through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Schematic diagram of the reaction of compound BA catalyzed by cytochrome P450 enzyme mutant to obtain compound 6β-OH-BA;
[0022] Figure 2 is the crystal structure diagram of compound A;
[0023] Figure 3 This is the HPLC chart of compound BA catalyzed by mutant Y256A+G87A+L82F+T209I+I81L. DETAILED DESCRIPTION
[0024] The technical solutions in the embodiments will be described clearly and completely below in combination with the embodiments and drawings of the present application. Obviously, the embodiments described below are only part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0025] Some of the terms and materials involved in this embodiment are explained below to facilitate understanding by those skilled in the art.
[0026] BA: Bisnoralcohol, the English name is Bisnoralcohol; the structural formula of BA is: .
[0027] 6β-OH-BA (or compound A): the reaction product of the above BA under the catalysis of cytochrome P450 enzyme mutant; the structural formula of 6β-OH-BA is: .
[0028] Unless otherwise specified, the specific composition of the culture medium used in the following examples is as follows:
[0029] LB liquid medium: weigh 2.5 g peptone, 1.25 g yeast powder and 2.5 g sodium chloride, stir and dissolve with appropriate amount of distilled water, dilute to 250 mL, and sterilize at 121℃ for 20 minutes. LB solid medium: add 3.75 g agar powder to LB liquid medium and sterilize by high pressure;
[0030] TB liquid medium: Add 3.0 g peptone, 6.0 g yeast powder and 1 mL glycerol, stir and dissolve with appropriate amount of distilled water, dilute to 225 mL, dispense into 22.5 mL bottles, and sterilize by autoclave. Separately, weigh 16.43 g (0.72 M) potassium dihydrogen phosphate trihydrate and 2.31 g (0.17 M) anhydrous potassium dihydrogen phosphate, stir and dissolve with appropriate amount of distilled water, dilute to 100 mL, and prepare potassium phosphate buffer. Before use, add 2.5 mL potassium phosphate buffer to each bottle of TB medium.
[0031] The cytochrome P450 enzyme mutants and their uses in the examples of the present application will be described in detail below.
[0032] First, the cytochrome P450 enzyme mutant of this example is described.
[0033] Cytochrome P450 enzyme mutants
[0034] In view of the fact that cytochrome P450 enzymes are widely used in the synthesis of various chemicals because of their higher catalytic activity than other P450 enzymes, this application selects the P450 BM3 mutant LG-23 (Li A, Acevedo-Rocha CG, D'Amore L, et al. Regio- and Stereoselective SteroidHydroxylation at C7 by Cytochrome P450 Monooxygenase Mutants. Angew Chem IntEd Engl. 2020;59(30):12499-12505.) that can perform 7β-hydroxylation reaction on testosterone to verify its catalytic effect on BA. This embodiment shows through relevant experiments that the reaction of LG-23 catalyzing BA to generate 6β-OH-BA has the problems of low yield and / or poor selectivity.
[0035] In view of this, in this example, mutation modification was performed using LG-23 as the initial template, aiming to find a P450 BM3 mutant with high yield and / or high selectivity for the substrate BA.
[0036] Specifically, this embodiment provides a cytochrome P450 enzyme mutant; the mutant has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO.2:
[0037] Y256A, Y256A+G87A, Y256A+G87A+L82W, Y256A+G87A+L82F, Y256A+G87A+L82 T, Y256A+G87A+T260S, Y256A+G87A+W330F, Y256A+G87A+W330T, Y256A+G87A +L82F+A74L、Y256A+G87A+L82F+A74M、Y256A+G87A+L82F+A74Q、Y256A+G87A+ L82F+T209V, Y256A+G87A+L82F+T209I, Y256A+G87A+L82F+T209F, Y256A+G87A +L82F+I263A, Y256A+G87A+L82F+A264G, Y256A+G87A+L82F+T209I+I81L, Y2 56A+G87A+L82F+T209I+I81T, Y256A+G87A+L82F+T209I+A184Q, Y256A+G87A+ L82F+ T209I+A184L, Y256A+G87A+L82F+T209I+A184F.
[0038] Among them, the amino acid sequence of the cytochrome P450 enzyme (SEQ ID NO. 2) is:
[0039]
[0040] It can be understood that this embodiment uses the amino acid sequence shown in SEQ ID NO. 2 as a template (basis), and on the basis of this amino acid sequence, the key active sites of the cytochrome P450 enzyme are mutated and modified to construct a mutant library; the cytochrome P450 enzyme mutant provided in this embodiment can selectively catalyze the 6β-hydroxylation reaction of sterol compounds (such as BA) to generate corresponding 6β-hydroxylated sterol compounds, and has excellent selectivity and / or high yield.
[0041] The nucleotide sequence of the cytochrome P450 enzyme in this example is shown in SEQ ID NO. 1, and the amino acid sequence is shown in the above SEQ ID NO. 2.
[0042] Specifically, the nucleotide sequence of the above cytochrome P450 enzyme (SEQ ID NO. 1) is:
[0043]
[0044] As a preferred embodiment of this embodiment, the mutant of this embodiment has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2: Y256A+G87A, Y256A+G87A+L82W, Y256A+G87A+L82F, Y256A+G87A+T260S, Y256A+G87A+L82F+A74L, Y256A+G87A+L82F+A74M, Y256A+G87A+L82F+A74Q, Y256A+G87A+L82F+T209V, Y256A+G87A+ L82F+T209I, Y256A+G87A+L82F+T209F, Y256A+G87A +L82F+I263A, Y256A+G87A+L82F+A264G, Y256A+G87A+L82F+T209I+I81L, Y2 56A+G87A+L82F+T209I+I81T, Y256A+G87A+L82F+T209I+A184Q, Y256A+G87A+ L82F+ T209I+A184L, Y256A+G87A+L82F+T209I+A184F.
[0045] It is understandable that the cytochrome P450 enzyme mutant of this embodiment can be mutated at the corresponding site by existing site-directed mutagenesis technology to obtain the target mutant. Among them, the mutant with multiple mutation points can be superimposed on the basis of a single mutant, that is, on the basis of a single mutant, a mutation is performed at another amino acid mutation site to obtain a mutant with multiple mutation points.
[0046] In summary, the cytochrome P450 enzyme mutant provided in this example can catalyze the 6β-hydroxylation reaction of various sterol compounds with excellent selectivity and / or high yield, indicating that the mutant has good application prospects in the preparation of 6β-hydroxysterol compounds from steroid compounds catalyzed by biological enzymes.
[0047] It should be understood that the cytochrome P450 enzyme mutant provided in this embodiment can improve the selectivity of sterol compounds to produce 6β-hydroxysterol compounds alone, can also improve the yield of sterol compounds to produce 6β-hydroxysterol compounds alone, or can simultaneously improve the selectivity and yield of sterol compounds to produce 6β-hydroxysterol compounds.
[0048] The selectivity is defined as: 6β-hydroxylation product / total product×100%; the yield is defined as: actual yield of target product (molar) / theoretical yield of target product (molar)×100%.
[0049] The mutant provided in this example is not limited to catalyzing bis-decanoyl alcohol (BA) to generate 6β-OH-BA. The mutant can also catalyze the 6β-hydroxylation reaction of other sterol compounds to generate the corresponding target product.
[0050] Next, the use of the above-mentioned cytochrome P450 enzyme mutant will be described.
[0051] Recombinant plasmid
[0052] The recombinant plasmid provided in this embodiment is a DNA molecule containing a nucleotide sequence encoding any of the above-mentioned cytochrome P450 enzyme mutants or its complementary sequence.
[0053] Illustratively, the recombinant plasmid of this embodiment can be selected from any one of the following:
[0054] pET-21b(+), pET-22b(+), pET-3a (+), pET-3d(+), pET-11a(+), pET-12a(+), pET-14b, pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b (+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a (+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), pET-41a(+), pET-41b(+), pET-42a (+), pET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQE2, pQE9, pQE30, pQE31, pQE32, pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET-C, pGEX-5X-1, pGEX-6p-1, pGEX-6p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-8, pUC-18, pUC-19, pPICZ A, pPICZα B, pPICZα C, pPIC3K, pPIC3.5K.
[0055] It is understandable that the recombinant plasmid of this embodiment can be prepared by a known preparation method, for example:
[0056] Using the expression vector containing the amino acid sequence shown in SEQ ID NO. 2 as a template, mutations were performed at the corresponding sites to obtain a recombinant plasmid containing a cytochrome P450 enzyme mutant.
[0057] For example, the above-mentioned expression vector can be selected from pET-28a; the above-mentioned expression vector containing the amino acid sequence shown in SEQ ID NO. 2 can be synthesized into the pET-28a vector by a gene synthesis company (such as Tianyi Huiyuan Gene Technology Co., Ltd.) to obtain the corresponding template (such as pET28a-LG-23 in the following Example 1).
[0058] Recombinant strains
[0059] It is understandable that the recombinant strain provided in this embodiment contains the above-mentioned recombinant plasmid.
[0060] In this embodiment, the host cell of the recombinant strain is a prokaryotic cell or a eukaryotic cell, and preferably the eukaryotic cell is a yeast cell.
[0061] The host cell may be a competent cell, and the competent cell is preferably a Pichia pastoris cell, Escherichia coli BL21 (DE3) or Transetta (DE3).
[0062] The recombinant strain of this embodiment can be prepared by using existing preparation methods, for example:
[0063] The prepared recombinant plasmid was transferred into Escherichia coli BL21 (DE3) for cultivation to obtain a recombinant strain.
[0064] The prepared recombinant strain usually needs to be stored in a refrigerator (such as -80°C).
[0065] Uses of cytochrome P450 enzyme mutants
[0066] As mentioned above, the cytochrome P450 enzyme mutant of this example can be used to catalyze the 6β-hydroxylation reaction of sterol compounds (such as BA) to generate 6β-hydroxylated sterol compounds.
[0067] It is understandable that, based on the use of cytochrome P450 enzyme mutants, the DNA molecules, recombinant plasmids, and recombinant strains of this embodiment can also be used to catalyze the 6β-hydroxylation reaction of sterol compounds to generate 6β-hydroxylated sterol compounds.
[0068] The preparation method of 6β-hydroxylated sterol compound will be described in detail below.
[0069] Illustratively, the method for preparing the 6β-hydroxylated sterol compound in this embodiment comprises:
[0070] (1) preparing a recombinant plasmid containing a cytochrome P450 enzyme mutant;
[0071] (2) transforming the recombinant plasmid into a host cell to obtain a recombinant strain;
[0072] (3) using sterol compounds as substrates, in the presence of O2 and NADPH, using the recombinant strain to catalyze 6β-hydroxylation of the sterol compounds to obtain 6β-hydroxylated sterol compounds;
[0073] The sterol compound is selected from one of the following compounds: .
[0074] The steps of the above preparation method will be further described below.
[0075] In step (1), preparing a recombinant plasmid encoding a cytochrome P450 enzyme mutant comprises:
[0076] Using the expression vector containing the amino acid sequence shown in SEQ ID NO. 2 as a template, mutations (site-directed mutagenesis) were performed at the corresponding sites to obtain a recombinant plasmid containing a cytochrome P450 enzyme mutant.
[0077] Among them, site-directed mutagenesis can adopt existing mutagenesis techniques, such as polymerase chain reaction (PCR) method.
[0078] In step (2), the recombinant plasmid is transformed into a host cell to obtain a recombinant strain, comprising:
[0079] The recombinant plasmid obtained in step (1) was transferred into Escherichia coli BL21 (DE3) for cultivation to obtain a recombinant strain.
[0080] In step (3), the sterol compound is used as a substrate, and in the presence of O2 and NADPH, the recombinant strain is used to catalyze the 6β-hydroxylation of the sterol compound to obtain the 6β-hydroxylated sterol compound, comprising:
[0081] The obtained recombinant bacteria were inoculated into TB liquid culture medium, and the bacteria were collected by centrifugation after shaking culture;
[0082] The bacteria were resuspended in a buffer (100 mM potassium phosphate buffer, pH=7.4), and sterol compounds were added to react in the presence of O2 and NADPH to obtain 6β-hydroxylated sterol compounds.
[0083] Among them, the above reaction requires the participation of oxygen so that the cytochrome P450 enzyme mutant catalyzes the sterol compound to generate the corresponding 6β-hydroxylated sterol compound, so the reaction can be carried out directly in the air environment; at the same time, NADPH is an electron donor and a condition for the cytochrome P450 enzyme mutant to be active, so the reaction usually needs to be carried out in a NADPH regeneration and reduction system.
[0084] Typically, the reaction conditions of step (3) are: reaction temperature of 20±10°C, rotation speed of 200±20 rpm, and reaction time of 12-24 h.
[0085] It can be understood that the sterol compound described in this embodiment is the substrate of the reaction.
[0086] For example, see Figure 1 When the substrate is BA, the cytochrome P450 enzyme mutant in this embodiment can selectively catalyze BA to directly undergo 6β-hydroxylation to obtain the corresponding 6β-hydroxylated sterol compound, namely, the product 6β-OH-BA.
[0087] Therefore, the cytochrome P450 enzyme mutant provided in this example can catalyze the 6β-hydroxylation reaction of various sterol compounds with excellent selectivity and / or high yield, indicating that the mutant has good application prospects in the preparation of 6β-hydroxysterol compounds (6β-hydroxylation products) from steroid compounds by bio-enzyme catalysis.
[0088] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate / explain the present application and are not used to limit the scope of the present application.
[0089] In the following examples, the materials, reagents and instruments used can be purchased from commercial sources unless otherwise specified.
[0090] Embodiment 1:
[0091] Synthesis and recombinant expression of template pET28a-LG-23
[0092] This example uses the LG-23 mutant (Li A, Acevedo-Rocha CG, D'Amore L, et al. Regio- and Stereoselective SteroidHydroxylation at the C7-Position by Cytochrome P450 Monooxygenase Mutants[J]. Angewandte Chemie, 2020, 59(30): 12499-12505.) reported in the literature as a template with 7β-hydroxylation activity on testosterone; in view of the fact that the template LG-23 has low yield and / or poor selectivity in the reaction of catalyzing BA to generate 6β-OH-BA. In this example, LG-23 is used as a parent template to synthesize and recombinantly express the template pET28a-LG-23; the nucleotide sequence of the parent template LG-23 is shown in SEQ ID NO. 1, and the amino acid sequence is shown in SEQ ID NO. 2;
[0093] Specifically:
[0094] The gene sequence of LG-23 was synthesized into the pET28a vector and named pET28a-LG-23;
[0095] Transform pET28a-LG-23 into E. coli In BL21(DE3) competent cells, recover the culture at 37℃, 200 rpm for 1 h, then apply an appropriate amount of bacterial solution on LB solid plate containing 50 μg / mL Kana resistance, and invert and culture at 37℃ overnight. On the second day, pick a single colony on the plate for activation, and transfer the activated bacterial solution to 25 mL TB medium containing 50 μg / mL Kana resistance at a dilution ratio of 1:50, and culture at 37℃, 220 rpm until the logarithmic growth phase (OD 600 0.6-0.8), add inducer IPTG and heme precursor (5ALA) to the final concentration of 0.2 mM and 0.5 mM respectively, and induce culture at 25°C, 180 rpm for 18 h;
[0096] The cells were collected by centrifugation at 6000 rpm and 4°C, washed twice with potassium phosphate buffer at pH 7.4, and disrupted by ultrasound. The cells were centrifuged at 4°C and 12000 rpm for 10 min, and the supernatant was used as a control for the subsequent activity screening of mutants.
[0097] For 1 mM catalytic substrate, the amount of wet bacteria used is 66 mg / mL.
[0098] Embodiment 2:
[0099] Structural identification of the product
[0100] Take 12.5 mL of the crude enzyme supernatant of Example 1 and add 100 mg / mL NADP + 250 μL, 1.25 mL of 20 mg / mL GDH, 500 μL of 2 M glucose, 250 μL of 100 mM substrate BA (dissolved in DMF), add potassium phosphate buffer with a pH of 7.4 to 25 mL, and react at 16°C and 220 rpm for 12-24 h. After the reaction is completed, add an equal volume of ethyl acetate to terminate the reaction, vortex mix, centrifuge at 6500 rpm for 10 minutes, collect the organic phase, repeat the above extraction operation three times, combine the organic phases, and remove the organic solvent by rotary evaporation to obtain the crude product;
[0101] The crude product was purified by silica gel column chromatography, eluted with petroleum ether:ethyl acetate in a volume ratio of 2:1 and 1:1 respectively; then the main product was separated and obtained as compound A by running the plate with a developing system of dichloromethane:methanol in a volume ratio of 20:1;
[0102] The structural characterization data of the compound are as follows:
[0103] Compound A: 1 H NMR (600 MHz, DMSO- d 6) δ 5.66 (s, 1H), 5.11 (dd, J = 2.9,1.1 Hz, 1H), 4.32 (t, J = 5.3 Hz, 1H), 4.15 (q, J = 2.9 Hz, 1H), 3.42 – 3.38(m, 1H), 3.10 – 3.03 (m, 1H), 2.49 – 2.40 (m, 1H), 2.22 – 2.15 (m, 1H), 2.04– 1.91 (m, 2H), 1.89 – 1.79 (m, 2H), 1.79 – 1.72 (m, 1H), 1.63 – 1.52 (m,2H), 1.51 – 1.36 (m, 3H), 1.28 (s, 3H), 1.26 – 1.21 (m, 2H), 1.14 – 1.10 (m,2H), 1.09 – 1.03 (m, 1H), 0.99 – 0.95 (m, 1H), 0.95 (d, J= 6.5 Hz, 3H), 0.88– 0.81 (m, 1H), 0.70 (s, 3H).
[0104] Among them, the s peak with an integral value of 1 at δ = 5.66 is the hydrogen at C-4, the peak with an integral value of 1 at δ = 5.11 is the hydrogen of OH connected to C-6, the t peak with an integral value of 1 at δ = 4.32 is the hydrogen of OH connected to C-22, the peak with an integral value of 1 at δ = 4.15 is the hydrogen of C-6, and the two m peaks with δ = 3.40 and 3.06 are the hydrogen of C-22;
[0105] Specifically, the crystal structure data of compound A is: Molecular formula: C 22 H 34 O3, molecular weight: 346.49; orthorhombic system, P212121 space group, unit cell parameters: a = 7.5617 (10) Å, b = 10.6736 (10) Å, c = 22.9261(2) Å, V= 1850.38(3) Å 3 , F(000) = 760.0, Z = 4, 8626 diffraction points, 3749 independent diffraction points (R int =0.0207). Full matrix least squares method was used for refinement, and the final R1 = 0.0319 [I ≥ 2σ (I)];
[0106] Among them, the crystal structure of compound A is shown in Figure 2 As shown;
[0107] Combining the above structural characterization data, crystal structure data and Figure 2 From the crystal structure diagram, it can be seen that the LG-23 mutant can catalyze BA to produce the corresponding 6β-hydroxylated sterol compound, namely the product 6β-OH-BA.
[0108] Embodiment 3:
[0109] Construction of cytochrome P450 enzyme mutants
[0110] Using pET28a-LG-23 plasmid as template, design mutation primers and place the base to be mutated in the middle of the primer. PCR amplification system (25 μL): 2.0 ng template, 1.0 μL each of upstream and downstream primers, 12.5 μL of 2 × Phanta Flash Master Mix, and finally add sterile distilled water to 25 μL;
[0111] The sequences of the upstream and downstream mutation primers used in this example are shown in Table 1 below:
[0112] Table 1: Sequences of upstream and downstream mutation primers
[0113]
[0114] PCR reaction procedure: (1) pre-denaturation at 98°C for 30 s; (2) denaturation at 98°C for 10 s; (3) set annealing temperature according to the mutant primer, annealing time 5 s; (4) extension at 72°C for 2 min, steps (2) to (4) for 30 cycles, and finally extension at 72°C for 1 min, and store PCR products at 12°C;
[0115] The above PCR products were digested with DpnI enzyme and then transferred into E. coli After the DH5α competent cells are recovered, an appropriate amount of bacterial solution is spread on an LB plate containing 50 μg / mL Kana resistance and incubated at 37°C overnight. Single colonies on the culture plate are verified, and 1-3 single colonies are selected for gene sequencing;
[0116] Among them, mutants with multiple mutation points are obtained by superimposing mutations on a single mutant using the same method as above;
[0117] The inducible expression of the mutants was consistent with that of the above templates.
[0118] Embodiment 4:
[0119] Activity screening of mutants
[0120] In this example, BA was used as an exemplary substrate to determine the catalytic activity of the mutants;
[0121] The wet cells obtained above were resuspended according to 1 g (wet cells): 15 mL (potassium phosphate buffer, pH = 7.4), 700 μL of the cell solution was taken for ultrasonic disruption, and the cell disruption solution was centrifuged at 4°C, 12000 rpm for 10 min. The reaction system was: 500 uL of supernatant, 10 μL of 100 mM BA (dissolved in DMF), 100 mg / mL NADP + 10 μL, 20 mg / mL GDH 50 μL, 2M glucose 20 μL, add pH 7.4 potassium phosphate buffer to a final volume of 1 mL;
[0122] In an air environment, the reaction was carried out at 16°C and 220 rpm for 12-24 h. After the reaction was completed, an equal volume of ethyl acetate was added for extraction, and the organic phase was collected. After the extraction operation was repeated three times, the organic phases were combined, the solvent was blown dry with a nitrogen blower, and then 1 mL of the sample dissolved in methanol was filtered with a 0.22 μm organic filter membrane. The content was detected by HPLC. The results are shown in Table 2:
[0123] Table 2: Activity test results of mutants
[0124] Mutants Yield (%) Selectivity(%) Template LG-23 2.5±0.0 66.6±1.5 Y256A 8.8±0.2 71.0±1.4 Y256A+G87A 28.6±2.2 86.5±0.0 Y256A+G87A+L82W 30.9±5.2 88.9±1.9 Y256A+G87A+L82F 39.8±2.9 88.5±2.0 Y256A+G87A+L82T 21.0±1.3 88.2±1.2 Y256A+G87A+T260S 27.4±3.7 69.6±0.2 Y256A+G87A+W330F 19.0±1.2 56.1±0.6 Y256A+G87A+W330T 28.1±0.0 74.7±0.1 Y256A+G87A+L82F+A74L 22.8±2.0 93.4±0.6 Y256A+G87A+L82F+A74M 29.7±2.9 93.7±0.0 Y256A+G87A+L82F+A74Q 25.2±1.4 81.6±1.2 Y256A+G87A+L82F+T209V 24.9±0.3 85.9±0.9 Y256A+G87A+L82F+T209I 50.0±2.5 94.2±0.2 Y256A+G87A+L82F+T209F 26.5±8.5 93.0±0.0 Y256A+G87A+L82F+I263A 24.7±1.9 90.4±0.2 Y256A+G87A+L82F+A264G 31.2±2.7 93.9±0.9 Y256A+G87A+L82F+T209I+I81L 64.0±1.0 95.5±0.4 Y256A+G87A+L82F+T209I+I81T 32.8±0.4 94.3±0.2 Y256A+G87A+L82F+T209I+A184Q 52.5±0.5 95.7±0.1 Y256A+G87A+L82F+T209I+A184L 34.2±4.4 93.0±2.6 Y256A+G87A+L82F+T209I+A184F 43.1±2.1 96.4±0.8
[0125] Note: The test results in Table 2 were obtained after three parallel reactions under the same reaction conditions. The selectivity is defined as: 6β-hydroxylation product / total product × 100%; the yield is defined as: actual yield of target product (moles) / theoretical yield of target product (moles) × 100%.
[0126] Combined with the test results in Table 2, the template (LG-23) has the defects of low yield and poor selectivity in catalyzing the reaction of BA to 6β-OH-BA. In this example, the key active sites are mutated and modified based on the template (LG-23), and a mutant with significantly improved yield and / or selectivity for catalyzing the 6β-hydroxylation reaction of sterol compounds can be obtained.
[0127] Among them, the yield and selectivity of mutant Y256A were significantly improved compared with the template (LG-23).
[0128] Furthermore, this example performs superimposed mutations on the basis of mutant Y256A to obtain a mutant with multiple mutation points, and simultaneously verifies the effects of other mutants on the yield and selectivity of catalyzing BA to produce 6β-OH-BA; combined with the test results in Table 2, the multiple mutants obtained in this example on the basis of mutant Y256A, relative to mutant Y256A, each multiple mutant catalyzes a significantly improved yield and / or selectivity of 6β-hydroxylation reaction of BA.
[0129] in, Figure 3 The HPLC diagram of mutant Y256A+G87A+L82F+T209I+I81L catalyzing compound BA; further combined with Table 2 and Figure 3 It can be seen that the mutant Y256A+G87A+L82F+T209I+I81L not only exhibits better catalytic activity, but also significantly improves the selectivity; among them, the yield is increased by 25 times and the selectivity can reach 95.5%.
[0130] It is understandable that the mutant provided in this embodiment can improve the selectivity of BA to generate 6β-hydroxylated products alone, can also improve the yield of BA to generate 6β-hydroxylated products alone, or can simultaneously improve the selectivity and yield of BA to generate 6β-hydroxylated products. Thus, this embodiment overcomes the defects of low yield and / or poor selectivity in the prior art template (LG-23) catalyzing the 6β-hydroxylation reaction of BA.
[0131] In summary, this example uses the amino acid sequence shown in SEQ ID NO. 2 as a template (basis), performs mutation modification on the key active sites of the template (basis), constructs a mutant library, and screens a series of mutants with significantly improved catalytic activity and / or selectivity; the cytochrome P450 enzyme mutant provided in this example can selectively catalyze the 6β-hydroxylation reaction of sterol compounds to generate corresponding 6β-hydroxylated sterol compounds (steroid drugs), and has excellent selectivity and / or high yield, indicating that the mutant has good application prospects in catalyzing steroid compounds to prepare 6β-hydroxysterol compounds.
[0132] The technical solutions provided in the embodiments of the present application are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present application. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present application. At the same time, for those skilled in the art, according to the embodiments of the present application, there will be changes in the specific implementation methods and application scopes. In summary, the contents of this specification should not be understood as limiting the present application.
Claims
1. A cytochrome P450 enzyme mutant, characterized in that: The mutant has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2: Y256A, Y256A+G87A, Y256A+G87A+L82W, Y256A+G87A+L82F, Y256A+G87A+L82 T, Y256A+G87A+T260S, Y256A+G87A+W330F, Y256A+G87A+W330T, Y256A+G87A +L82F+A74L、Y256A+G87A+L82F+A74M、Y256A+G87A+L82F+A74Q、Y256A+G87A+ L82F+T209V、Y256A+G87A+ L82F+T209I, Y256A+G87A+L82F+T209F, Y256A+G87A +L82F+I263A, Y256A+G87A+L82F+A264G, Y256A+G87A+L82F+T209I+I81L, Y2 56A+G87A+L82F+T209I+I81T, Y256A+G87A+L82F+T209I+A184Q, Y256A+G87A+ L82F+ T209I+A184L, Y256A+G87A+L82F+T209I+A184F.
2. A DNA molecule, characterized in that The DNA molecule is a nucleotide sequence encoding the cytochrome P450 enzyme mutant according to claim 1 or its complementary sequence.
3. A recombinant plasmid, characterized in that: The recombinant plasmid contains the DNA molecule as claimed in claim 2.
4. A recombinant strain, characterized in that: The recombinant strain contains the recombinant plasmid as claimed in claim 3.
5. The recombinant strain according to claim 4, characterized in that The host cell of the recombinant strain is a prokaryotic cell or a eukaryotic cell, and the eukaryotic cell is a yeast cell.
6. The recombinant strain according to claim 4, characterized in that The host cells of the recombinant strain are competent cells.
7. The recombinant strain according to claim 6, characterized in that The competent cells are Pichia pastoris cells, Escherichia coli BL21 (DE3) or Transetta (DE3).
8. Use of the cytochrome P450 enzyme mutant according to claim 1, the DNA molecule according to claim 2, the recombinant plasmid according to claim 3 or the recombinant strain according to any one of claims 4 to 7 for catalyzing the 6β-hydroxylation reaction of sterol compounds to generate 6β-hydroxylated sterol compounds, characterized in that: The sterol compound is selected from one of the following compounds: 。 9. The use according to claim 8, characterized in that The preparation method of the 6β-hydroxylated sterol compound comprises: preparing a recombinant plasmid containing a cytochrome P450 enzyme mutant; Transforming the recombinant plasmid into a host cell to obtain a recombinant strain; Using sterol compounds as substrates, in the presence of O2 and NADPH, the recombinant strain is used to catalyze the 6β-hydroxylation reaction of the sterol compounds to obtain 6β-hydroxylated sterol compounds.
